Dr. Patni is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
66 Lisa Dr
Chatham, NJ 07928Phone+1 973-701-1084
Summary
- I am a cardiologist, who has been focused on clinical drug development in the pharmaceutical / biotechnology industry. To date, I have been involved in approximately 20 drug development programs, including dofetilide, quinapril, amlodipine, sildenafil, aliskiren, and macitentan. My approach has been partnering with academia and the FDA to design and execute pragmatic yet robust clinical trials to ultimately inform the creation of product labels, that are truthful and clinically relevant. In this way, the product label can inform responsible and appropriate utilization by the prescribing physician.
Education & Training
- Montefiore Medical Center/Albert Einstein College of Medicine (Montefiore)Fellowship, Cardiovascular Disease, 1998 - 2000
- Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1995 - 1998
- Icahn School of Medicine at Mount SinaiInternship, Transitional Year, 1994 - 1995
- Icahn School of Medicine at Mount SinaiClass of 1994
Certifications & Licensure
- CA State Medical License 2012 - 2026
- NJ State Medical License 2009 - 2025
- NY State Medical License 1996 - 2025
- PA State Medical License 1997 - 1998
Publications & Presentations
PubMed
- 315 citationsSelective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 DiabetesMurray Epstein, Gordon H. Williams, Myron H. Weinberger, Andrew J. Lewin, Scott Krause
Clinical Journal of the American Society of Nephrology. 2006-09-01 - 7 citationsSafety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.Jeffrey A. Cohen, Samuel F. Hunter, Theodore R Brown, Mark Gudesblatt, Ben Thrower
Multiple Sclerosis. 2019-04-01 - 19 citationsImpact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.Rajesh Pahwa, Stuart Isaacson, Joohi Jimenez-Shaheed, Irene A. Malaty, Andres Deik
Parkinsonism & Related Disorders. 2019-03-01
Press Mentions
- Portola Pharmaceuticals Announces Results Demonstrating Andexxa® Was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related BleedsMarch 16th, 2020
- Portola Pharmaceuticals Unveils Data on Andexxa in Patients with Multiple Types of Factor Xa Inhibitor-Related BleedsMarch 16th, 2020
- New Data Demonstrates Andexxa® Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa InhibitorsMarch 5th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: